JP7527984B2 - 重度の便秘を治療するための組成物及び方法 - Google Patents

重度の便秘を治療するための組成物及び方法 Download PDF

Info

Publication number
JP7527984B2
JP7527984B2 JP2020573085A JP2020573085A JP7527984B2 JP 7527984 B2 JP7527984 B2 JP 7527984B2 JP 2020573085 A JP2020573085 A JP 2020573085A JP 2020573085 A JP2020573085 A JP 2020573085A JP 7527984 B2 JP7527984 B2 JP 7527984B2
Authority
JP
Japan
Prior art keywords
constipation
dgat1
pharmaceutical composition
opioid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518431A (ja
JPWO2019178492A5 (https=
JP2021518431A5 (https=
Inventor
ケー． ハブバード，ブライアン
エイチ． セラーノ－ウー，マイケル
Original Assignee
アンジ ファーマシューティカルズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンジ ファーマシューティカルズ インコーポレーテッド filed Critical アンジ ファーマシューティカルズ インコーポレーテッド
Publication of JP2021518431A publication Critical patent/JP2021518431A/ja
Publication of JPWO2019178492A5 publication Critical patent/JPWO2019178492A5/ja
Publication of JP2021518431A5 publication Critical patent/JP2021518431A5/ja
Application granted granted Critical
Publication of JP7527984B2 publication Critical patent/JP7527984B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020573085A 2018-03-16 2019-03-15 重度の便秘を治療するための組成物及び方法 Active JP7527984B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
US62/644,033 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (4)

Publication Number Publication Date
JP2021518431A JP2021518431A (ja) 2021-08-02
JPWO2019178492A5 JPWO2019178492A5 (https=) 2022-02-21
JP2021518431A5 JP2021518431A5 (https=) 2022-02-21
JP7527984B2 true JP7527984B2 (ja) 2024-08-05

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573085A Active JP7527984B2 (ja) 2018-03-16 2019-03-15 重度の便秘を治療するための組成物及び方法

Country Status (17)

Country Link
US (4) US11224590B2 (https=)
EP (1) EP3765012B1 (https=)
JP (1) JP7527984B2 (https=)
KR (1) KR102747096B1 (https=)
CN (1) CN111936137B (https=)
AU (1) AU2019234956B2 (https=)
BR (1) BR112020018790A2 (https=)
EA (1) EA202092190A1 (https=)
FI (1) FI3765012T3 (https=)
IL (1) IL277332B2 (https=)
MX (1) MX2020009604A (https=)
MY (1) MY205335A (https=)
PE (1) PE20210158A1 (https=)
PH (1) PH12020551468A1 (https=)
SG (1) SG11202008971VA (https=)
TW (1) TWI704917B (https=)
WO (1) WO2019178492A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277332B2 (en) 2018-03-16 2025-01-01 Anji Pharmaceuticals Inc Preparations and methods for treating severe constipation
KR20220052459A (ko) 2020-10-21 2022-04-28 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
WO1999067268A1 (en) 1998-06-24 1999-12-29 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
JP2004502686A (ja) 2000-06-30 2004-01-29 スージェン・インコーポレーテッド ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
KR100772297B1 (ko) 2002-11-22 2007-11-02 니뽄 다바코 산교 가부시키가이샤 융합 비시클릭 질소-함유 헤테로사이클
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
EP1653969A4 (en) 2003-08-07 2006-12-20 Japan Tobacco Inc PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
EP1718309A2 (en) 2004-01-30 2006-11-08 Japan Tobacco, Inc. Anorectic compounds
WO2006004200A1 (ja) 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
JP2008516978A (ja) 2004-10-15 2008-05-22 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満症の処置のためのビフェニル−４−イル−カルボニルアミノ酸誘導体の製造および使用
US7795283B2 (en) 2004-12-14 2010-09-14 Astrazeneca Ab Oxadiazole derivative as DGAT inhibitors
KR20080000652A (ko) 2005-04-19 2008-01-02 바이엘 파마슈티칼스 코포레이션 아릴 알킬산 유도체 및 그의 용도
WO2007002740A2 (en) 2005-06-28 2007-01-04 E. I. Du Pont De Nemours And Company Buffer compositions
EP2402320A1 (en) * 2006-03-31 2012-01-04 Novartis AG Anorectic agents
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
WO2009126624A1 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
MA34097B1 (fr) * 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
WO2011126967A1 (en) * 2010-04-08 2011-10-13 Medicinova, Inc. Methods and compositions for the treatment of irritable bowel syndrome
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013130370A2 (en) * 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
CN104936581A (zh) * 2012-08-29 2015-09-23 萨利克斯药品有限公司 用于治疗便秘和相关胃肠道疾病和疾病状态的泻药组合物和方法
US9895423B2 (en) * 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
IL277332B2 (en) 2018-03-16 2025-01-01 Anji Pharmaceuticals Inc Preparations and methods for treating severe constipation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry，2017年，60(11)，pp.4657-4664

Also Published As

Publication number Publication date
KR102747096B1 (ko) 2024-12-26
IL277332B1 (en) 2024-09-01
US20260000651A1 (en) 2026-01-01
CA3093970A1 (en) 2019-09-19
AU2019234956B2 (en) 2025-01-30
US11819495B2 (en) 2023-11-21
EP3765012B1 (en) 2026-03-04
MY205335A (en) 2024-10-16
JP2021518431A (ja) 2021-08-02
US20240293376A1 (en) 2024-09-05
WO2019178492A1 (en) 2019-09-19
PH12020551468A1 (en) 2021-09-01
BR112020018790A2 (pt) 2020-10-13
AU2019234956A1 (en) 2020-10-01
EP3765012A4 (en) 2021-12-15
IL277332A (en) 2020-10-29
IL277332B2 (en) 2025-01-01
US20220193044A1 (en) 2022-06-23
CN111936137A (zh) 2020-11-13
KR20200136428A (ko) 2020-12-07
EP3765012A1 (en) 2021-01-20
EA202092190A1 (ru) 2020-11-19
TWI704917B (zh) 2020-09-21
PE20210158A1 (es) 2021-01-26
TW201944995A (zh) 2019-12-01
MX2020009604A (es) 2023-01-25
US11224590B2 (en) 2022-01-18
US20190282549A1 (en) 2019-09-19
SG11202008971VA (en) 2020-10-29
US12343334B2 (en) 2025-07-01
CN111936137B (zh) 2023-09-08
FI3765012T3 (fi) 2026-04-17

Similar Documents

Publication Publication Date Title
US20260000651A1 (en) Compositions and methods for treating severe constipation
CA2802407C (en) Treatment of gout and hyperuricemia
JP2012500800A (ja) 神経因性疼痛の治療法
TW202011965A (zh) 嗜中性球彈性蛋白酶抑制劑在肝病中之用途
CN108882744B (zh) 含有益智提取物的组合物以及益智提取物的用途
JP2010527985A (ja) 急性躁病を治療するための医薬組成物および方法
EP2059234A1 (en) Method for reducing or alleviating inflammation in the digestive tract
RU2307651C2 (ru) Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря
CA3093970C (en) Compositions and methods for treating severe constipation
CN117695277B (zh) 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途
CA3191276A1 (en) Ionic liquid formulations for treating diabetes
CN117771238B (zh) 苯丙酸类似物在治疗或预防代谢紊乱中的用途
CN110831590A (zh) 含有培马贝特的医药
US20100305074A1 (en) Niacin-based pharmaceutical compositions
Kavadi Role of Sotagliflozin in Managing Heart Failure in Diabetes
TWI609689B (zh) 改善腎臟病患者之腎臟功能和/或心臟功能的方法
KR20250168617A (ko) 염증성 장 질환의 치료를 위한 약학적 조성물
JP2025528218A (ja) ピロリ菌（Ｈ．ｐｙｌｏｒｉ）感染症を予防または処置する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240724

R150 Certificate of patent or registration of utility model

Ref document number: 7527984

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150